3-Methyl-6-propan-2-ylimidazo[1,2-b]pyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Methyl-6-propan-2-ylimidazo[1,2-b]pyridazine
• 英文别名: 3-methyl-6-propan-2-ylimidazo[1,2-b]pyridazine
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.23
• InChiKey: NIFIKJNUWKZIPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150274696A1

  公开（公告）日：2015-10-01

  Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R 2 is a bicyclic heterocycle, and R 1 , R 3 , R 4 , R 5 and R 6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.

  具有以下式(I)或其立体异构体或药物可接受的盐的化合物，其中R2是双环杂环，R1、R3、R4、R5和R6如此定义，可用作激酶调节剂，包括IRAK-4调节剂。
• THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160083375A1

  公开（公告）日：2016-03-24

  Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R 7 , are useful as kinase modulators, including IRAK-4 modulation.

  具有以下化学式的化合物：或其对映异构体、顺反异构体或药用可接受的盐，其中X为N或C—R7，可用作激酶调节剂，包括IRAK-4调节。
• Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10227340B2

  公开（公告）日：2019-03-12

  Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

  具有下式的化合物 或其对映体、非对映体或药学上可接受的盐，其中 X 为 N 或 C-R7，可用作激酶调节剂，包括 IRAK-4 调节剂。
• MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF
  申请人：ANGEX PHARMACEUTICAL, INC.

  公开号：US20200385386A1

  公开（公告）日：2020-12-10

  The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.
• US9242976B2
  申请人：——

  公开号：US9242976B2

  公开（公告）日：2016-01-26